BEDFORD, Mass.--(BUSINESS WIRE)--May 26, 2021--
Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences:
Jefferies Virtual Healthcare Conference
Date: Tuesday, June 1, 2021
Analyst-hosted fireside chat: 4:00 PM ET
The JMP Securities Life Sciences Conference
Date: Wednesday, June 16, 2021
Analyst-hosted fireside chat: 12:00 PM ET
Raymond James Healthcare Conference 2021
Date: Wednesday, June 23, 2021
New Treatments for Dry Eye Panel: 1:20 PM ET
Management will be available throughout the day for virtual investor meetings at all of the conferences. If you plan to attend at least one of the conferences and are interested in meeting with management, please contact your Jefferies, JMP Securities or Raymond James representative.
A live webcast of the fireside chats during the Jefferies Virtual Healthcare Conference and The JMP Securities Life Sciences Conference can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix has received a target action date under the Prescription Drug User Fee Act, commonly known as PDUFA, of October 18, 2021, for a supplemental new drug application to include the treatment of ocular itching associated with allergic conjunctivitis as an additional approved indication of DEXTENZA. Ocular Therapeutix’s earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix is currently evaluating each of OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease in Phase 2 clinical trials. Also, in collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal injection) is in pre-clinical development as an extended-delivery formulation of aflibercept for the treatment of retinal diseases. Ocular Therapeutix's first product, ReSure® Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005239/en/
Chief Financial Officer
Westwicke, an ICR Company
Chris Brinzey, 339-970-2843
Senior Vice President, Commercial
Source: Ocular Therapeutix, Inc.